Maze Therapeutics MAZE
NASDAQ MAZE
$26.21 +0.34 (+1.32%)
As of: Sep 4, 2026 · 3:59 PM EDT

Maze Therapeutics (MAZE) Gross Profit (2025 - 2026)

Maze Therapeutics (MAZE) posted Gross Profit of $18.2 million for Q1 2026, up 1633.95% sequentially from -$1.2 million in Q1 2025, and up 1633.95% YoY from $1.1 million in Q1 2025.

Analysis

Maze Therapeutics (MAZE) Gross Profit (2025 - 2026) Analysis & Trends

Maze Therapeutics has reported Gross Profit for 2 years, with the latest figure at $18.2 million in Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Maze Therapeutics 1.55 Bn 1.55 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 18.21 Mn
Mar 31, 2025 -1.19 Mn